Antimicrobial Resistance – Navigating obstacles in R&D and commercialization
The lack of innovation surrounding the development of new antibiotics has resulted in an alarming situation, given the rising threat of antimicrobial resistance (AMR).
As a result, there is no single or straightforward way to combat AMR, nor to galvanize development of novel antibiotics. Although some positive measures have been introduced, further – and larger scale – action is needed.
Since the initial era of discovery in the mid-20th century, there has been a lackluster level of innovation in the antibiotics field, and today there are few novel antibiotic classes in development despite the urgency of medical need.
The lagging antimicrobial innovation has certainly made its impact felt. Estimates suggest that resistant infections underlie nearly 700,000 global deaths each year – a figure projected by some to rise to 10 million each year by 2050.
New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases, resulting in prolonged illness, disability, and death. Each year in the US alone, the CDC reports that at least 2 million people contract an antibiotic-resistant infection, with an estimated annual attributable death toll of 23,000.
You may also be interested in…
Can AI really help you understand what matters in your market?
The impact of AI across our industry will be profound. It’s already driving faster identification of novel drug targets and drug discovery, better patient identification, accelerated drug development, earlier diagnosis, and more personalized healthcare.
Brain Awareness Week
Brain Awareness Week is a global campaign held every March that aims to increase public support and excitement for brain science.
Rare Diseases, Pharma’s Perennial Hitmaker
February 29th is the rarest day of the year, and this was in fact the reason why Rare Disease Day was established on this day 16 years ago by the European Organisation for Rare Diseases, commemorating the 25th anniversary of the U.S. Orphan Drug Act.